{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:14:12Z","timestamp":1772003652059,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01631-8","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:22:28Z","timestamp":1768486948000},"page":"1255-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes in Patients with Psoriasis Following Apremilast Treatment: Results from the German Psoriasis Registry PsoBest"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan J.","family":"Rustenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5004-0982","authenticated-orcid":false,"given":"Ralph","family":"von Kiedrowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Amouzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1797-0510","authenticated-orcid":false,"given":"Myriam","family":"Cordey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Mrowietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"1631_CR1","first-page":"45","volume":"22","author":"K Hagenstr\u00f6m","year":"2024","unstructured":"Hagenstr\u00f6m K, M\u00fcller K, Garbe C, Augustin M. Prevalence of psoriasis and psoriatic arthritis in Germany\u2014analysis of claims data. J Dtsch Dermatol Ges. 2024;22:45\u201354.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1631_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000119415","volume":"216","author":"M Augustin","year":"2008","unstructured":"Augustin M, Kr\u00fcger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216:366\u201372.","journal-title":"Dermatology"},{"key":"1631_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12:61\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1631_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2340\/00015555-0770","volume":"90","author":"M Augustin","year":"2010","unstructured":"Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147\u201351.","journal-title":"Acta Derm Venereol"},{"key":"1631_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265741","volume":"17","author":"J Augustin","year":"2022","unstructured":"Augustin J, Wolf S, Stephan B, Augustin M, Andrees V. Psoriasis comorbidities in Germany: a population-based study on spatiotemporal variations. PLoS ONE. 2022;17:e0265741.","journal-title":"PLoS ONE"},{"key":"1631_CR6","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/jdv.19192","volume":"37","author":"U Mrowietz","year":"2023","unstructured":"Mrowietz U, S\u00fcmb\u00fcl M, Gerdes S. Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation. J Eur Acad Dermatol Venereol. 2023;37:1731\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1631_CR7","first-page":"467","volume":"121","author":"U Mrowietz","year":"2024","unstructured":"Mrowietz U, Lauffer F, Sondermann W, Gerdes S, Sewerin P. Psoriasis as a systemic disease. Dtsch Arztebl Int. 2024;121:467\u201372.","journal-title":"Dtsch Arztebl Int"},{"key":"1631_CR8","first-page":"934","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: treatment goals and treatment recommendations. JDDG J Dtsch Dermatol Ges. 2021;19:934\u2013150.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1631_CR9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445\u201386.","journal-title":"J Am Acad Dermatol"},{"key":"1631_CR10","unstructured":"Otezla [summary of product characteristics]. Breda, Netherlands: Amgen Europe B.V., 2022."},{"key":"1631_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s13555-021-00658-x","volume":"12","author":"K Reich","year":"2022","unstructured":"Reich K, Korge B, Magnolo N, et al. Quality-of-life outcomes, effectiveness and tolerability of apremilast in patients with plaque psoriasis and routine German dermatology care: results from LAPIS-PSO. Dermatol Ther (Heidelb). 2022;12:203\u201321.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1631_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase\u00a0III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"1631_CR13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52\u00a0weeks: a phase\u00a0III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399.","journal-title":"Br J Dermatol"},{"key":"1631_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.16431","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Kleyn CE, Conrad C, et al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35:123\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1631_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ad.2021.05.010","volume":"112","author":"P Herranz","year":"2021","unstructured":"Herranz P, Trasobares L, Mateu A, et al. Characterization and outcomes in patients treated with apremilast in routine clinical practice in Spain: results from the APPRECIATE study. Actas Dermosifiliogr (Engl Ed). 2021;112:817\u201327.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"1631_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s12325-021-01981-7","volume":"39","author":"PD Ghislain","year":"2022","unstructured":"Ghislain PD, Lambert J, Hoai XL, et al. Real-life effectiveness of apremilast for the treatment of psoriasis in Belgium: results from the observational OTELO study. Adv Ther. 2022;39:1068\u201380.","journal-title":"Adv Ther"},{"key":"1631_CR17","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1007\/s12325-023-02516-y","volume":"40","author":"C Giofr\u00e8","year":"2023","unstructured":"Giofr\u00e8 C, Fabbrocini G, Potenza C, et al. Real-world apremilast use for treatment of plaque psoriasis in Italy: patient perspective, characteristics, and clinical outcomes from the DARWIN study. Adv Ther. 2023;40:3021\u201337.","journal-title":"Adv Ther"},{"key":"1631_CR18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s13555-023-00933-z","volume":"13","author":"D Jullien","year":"2023","unstructured":"Jullien D, Richard MA, Halioua B, Bessette C, Derancourt C, Bouloc A. The needs of patients with psoriasis and benefits of apremilast in French clinical practice: results from the observational REALIZE study. Dermatol Ther (Heidelb). 2023;13:1361\u201376.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1631_CR19","first-page":"48","volume":"12","author":"M Augustin","year":"2014","unstructured":"Augustin M, Spehr C, Radtke MA, et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. JDDG J Dtsch Dermatol Ges. 2014;12:48\u201357.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1631_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","volume":"24","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Hatemi G, Paris M, et al. Apremilast long-term safety up to 5\u00a0years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Beh\u00e7et\u2019s syndrome. Am J Clin Dermatol. 2023;24:809\u201320.","journal-title":"Am J Clin Dermatol"},{"key":"1631_CR21","first-page":"997","volume":"159","author":"MK Basra","year":"2008","unstructured":"Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997\u20131035.","journal-title":"Br J Dermatol"},{"key":"1631_CR22","unstructured":"OTEZLA [prescribing information]. Thousand Oaks, CA: Amgen Inc., 2021."},{"key":"1631_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","volume":"77","author":"J Crowley","year":"2017","unstructured":"Crowley J, Tha\u00e7i D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for \u2265156\u00a0weeks from 2 phase\u00a03, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310-7.e1.","journal-title":"J Am Acad Dermatol"},{"key":"1631_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","volume":"307","author":"K Reich","year":"2015","unstructured":"Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307:875\u201383.","journal-title":"Arch Dermatol Res"},{"key":"1631_CR25","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80:1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"key":"1631_CR26","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1204a179","volume":"12","author":"A Tsentemeidou","year":"2022","unstructured":"Tsentemeidou A, Sotiriou E, Sideris N, et al. Apremilast in psoriasis patients with serious comorbidities: a case series and systematic review of literature. Dermatol Pract Concept. 2022;12:e2022179.","journal-title":"Dermatol Pract Concept"},{"key":"1631_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.33590\/emjrheumatol\/10314411","volume":"6","author":"A Chan","year":"2019","unstructured":"Chan A, Rigler K, Herdman L. Real-world experience of apremilast in treating psoriatic arthritis patients with comorbidities. EMJ Rheumatol. 2019;6:134\u20139.","journal-title":"EMJ Rheumatol"},{"key":"1631_CR28","first-page":"611","volume":"21","author":"T Heidbrede","year":"2023","unstructured":"Heidbrede T, Mevius A, Kessel S, Wilke T, Maywald U, Thiem A. Real-world systemic treatment of patients with psoriasis: a retrospective study based on German claims data. JDDG J Dtsch Dermatol Ges. 2023;21:611\u20139.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1631_CR29","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1111\/jdv.15804","volume":"33","author":"AC Fougerousse","year":"2019","unstructured":"Fougerousse AC, Maccari F, Beauchet A, et al. Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical setting. J Eur Acad Dermatol Venereol. 2019;33:e476\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1631_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27\u201333.","journal-title":"Dermatology"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01631-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01631-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01631-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:41:24Z","timestamp":1772001684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01631-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01631-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthias Augustin: Consultant for, paid speaker for, and\/or recipient of institutional research grants from AbbVie, Almirall, Amgen, Bayer Healthcare, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Centocor, Lilly, Fresenius, Galderma, GlaxoSmithKline, Hexal, Janssen, Klinge, LEO Pharma, MC2, Medac, Merck, MSD, Novartis, Pfizer, Sandoz, Sun Pharma, UCB, and Viatris. Stephan J.\u00a0Rustenbach: No conflicts of interest to declare. Ralph von Kiedrowski: Consultant and\/or paid speaker for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion HC, Fresenius Kabi, Galderma, Hexal, Lilly, Janssen, LEO Pharma, MoonLake, Novartis, Pfizer, Sanofi-Aventis, and UCB. Hamid Amouzadeh: Employment and stock ownership in Amgen. Kathy Tran: Employment and stock ownership in Amgen. Myriam Cordey: Employment and stock ownership in Amgen. Ulrich Mrowietz: Advisor for, received speakers\u2019 honoraria and grants from, and participated in clinical trials for AbbVie, Aditxt, Almirall, Amgen, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dr. Reddy\u2019s, Lilly, Foamix, Formycon, Immunic, Janssen, LEO Pharma, Medac, MetrioPharm, Novartis, Phi-Stone, Pierre Fabre, Sanofi-Aventis, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The PsoBest registry was planned and performed under strict rules of patient protection as suggested by German and European laws, the Declaration of Helsinki, and Good Clinical Practice as described in the International Council for Harmonisation Guideline E6. Consent from the ethics committee of the physician\u2019s chamber of the Federal State of Hamburg was obtained (Ethikkommission der \u00c4rztekammer Hamburg, Weidestr. 122b, 22083 Hamburg, Bearbeitungs-Nr. 2805). Signed informed consent was required before study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}